Reviewing Pharming Group (PHAR) & Its Competitors

Pharming Group (NASDAQ:PHAR – Get Free Report) is one of 843 publicly-traded companies in the “Biotechnology” industry, but how does it weigh in compared to its peers? We will compare Pharming Group to related companies based on the strength of its institutional ownership, valuation, earnings, analyst recommendations, dividends, risk and profitability.

Risk & Volatility

Pharming Group has a beta of -0.05, meaning that its share price is 105% less volatile than the S&P 500. Comparatively, Pharming Group’s peers have a beta of -1.83, meaning that their average share price is 283% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and recommmendations for Pharming Group and its peers, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Pharming Group 0 2 3 0 2.60
Pharming Group Competitors 9941 15335 45756 1605 2.54

Pharming Group presently has a consensus price target of $39.67, suggesting a potential upside of 223.55%. As a group, “Biotechnology” companies have a potential upside of 133.59%. Given Pharming Group’s stronger consensus rating and higher possible upside, equities research analysts clearly believe Pharming Group is more favorable than its peers.

Profitability

This table compares Pharming Group and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Pharming Group 6.23% 8.70% 4.93%
Pharming Group Competitors -12,224.75% -204.85% -31.52%

Earnings & Valuation

This table compares Pharming Group and its peers revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Pharming Group $376.13 million $2.85 million 38.31
Pharming Group Competitors $688.58 million $7.69 million -18.44

Pharming Group’s peers have higher revenue and earnings than Pharming Group. Pharming Group is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Insider and Institutional Ownership

0.0% of Pharming Group shares are owned by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are owned by institutional investors. 2.1% of Pharming Group shares are owned by company insiders. Comparatively, 13.1% of shares of all “Biotechnology” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Pharming Group beats its peers on 7 of the 13 factors compared.

Pharming Group Company Profile

(Get Free Report)

Pharming Group N.V. is a biotechnology company headquartered in Leiden, the Netherlands, that develops and commercializes medicines for rare and underserved diseases. Founded in 1988, the company has built its business around treatments for disorders involving the immune system. Its marketed products include Ruconest (conestat alfa), a recombinant human C1 esterase inhibitor used to treat acute attacks of hereditary angioedema, and Joenja (leniolisib), an oral treatment for activated phosphoinositide 3-kinase delta syndrome (APDS).

Receive News & Ratings for Pharming Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharming Group and related companies with MarketBeat.com's FREE daily email newsletter.